Essex LLC’s Novo Nordisk NVO Stock Holding History

Essex LLC’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$230K	Buy	+4,800	New	+$206K	0.03%	165
2026 Q1	–	Sell	-6,242	Closed	-$318K	–	183
2025 Q4	$318K	Buy	6,242 +75	+1%	+$3.83K	0.06%	141
2025 Q3	$342K	Buy	6,167 +973	+19%	+$57K	0.06%	129
2025 Q2	$358K	Buy	5,194 +643	+14%	+$43.7K	0.07%	121
2025 Q1	$316K	Hold	4,551	–	–	0.07%	124
2024 Q4	$391K	Sell	4,551 -310	-6%	-$33.5K	0.08%	114
2024 Q3	$579K	Hold	4,861	–	–	0.12%	103
2024 Q2	$694K	Buy	4,861 +177	+4%	+$23.5K	0.16%	96
2024 Q1	$601K	Buy	4,684 +90	+2%	+$10.7K	0.14%	96
2023 Q4	$475K	Buy	4,594 +10	+0.2%	+$989	0.12%	107
2023 Q3	$417K	Buy	4,584 +184	+4%	+$16.2K	0.12%	107
2023 Q2	$356K	Sell	4,400 -524	-11%	-$42.8K	0.1%	111
2023 Q1	$333K	Hold	4,924	–	–	0.1%	116
2022 Q4	$333K	Hold	4,924	–	–	0.1%	116
2022 Q3	$245K	Sell	4,924 -100	-2%	-$5.36K	0.08%	129
2022 Q2	$280K	Hold	5,024	–	–	0.09%	127
2022 Q1	$279K	Hold	5,024	–	–	0.08%	140
2021 Q4	$281K	Sell	5,024 -876	-15%	-$47.5K	0.08%	147
2021 Q3	$283K	Buy	+5,900	New	+$285K	0.08%	148

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Essex LLC's NVO Position: Q2 2026 in Review

Essex LLC opened a new position in Novo Nordisk (NVO) in Q2 2026: 4,800 shares worth $230K. The stake represents 0.03% of the portfolio and ranks #165 among its holdings. This is a return to the name: Essex LLC previously reported a position in NVO as recently as Q4 2025.

Essex LLC first reported a position in NVO in Q3 2021 and has held it in 19 quarters since. The position peaked at $694K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Essex LLC held 4,800 shares of Novo Nordisk worth $230K as of Q2 2026.
Novo Nordisk was a new Essex LLC position in Q2 2026.
Novo Nordisk made up 0.03% of Essex LLC's portfolio in Q2 2026, its #165 holding.
Essex LLC first reported a position in Novo Nordisk in Q3 2021 and has held it in 19 quarters since.
Essex LLC's Novo Nordisk position peaked at $694K in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Essex LLC's 13F filing for Q2 2026, filed 24 Jul 2026.